Phlebotomy and Polycystic Ovary Syndrome

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
HyperandrogenismMetabolic Cardiovascular Syndrome
Interventions
PROCEDURE

Phlebotomy

Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.

DRUG

ethinylestradiol

35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.

DRUG

Cyproterone Acetate

2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.

Trial Locations (1)

28034

Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Manuel Luque Ramírez

OTHER

NCT02460445 - Phlebotomy and Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter